

09/871183

Search results  
for Final Rejection**WEST****Freeform Search****Database:**

US Patents Full-Text Database  
 US Pre-Grant Publication Full-Text Database  
 JPO Abstracts Database  
 EPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

**Term:**

(transcomplementary or trans near complementary or  
 trans near complement\$) near10 (reovir\$ or herpes\$  
 or AAV or EBV or lentivir\$ or retrovir\$)

**Display:**

100 Documents in Display Format: - Starting with Number 1

Generate: ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show S Numbers

Edit S Numbers

Preferences

Cases

**Search History**

DATE: Thursday, December 11, 2003 [Printable Copy](#) [Create Case](#)

**Set Name Query**  
 side by side

**Hit Count Set Name**  
 result set

DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR

<u>L10</u>	(transcomplementary or trans near complementary or trans near complement\$) near10 (reovir\$ or herpes\$ or AAV or EBV or lentivir\$ or retrovir\$)	38	<u>L10</u>
<u>L9</u>	L6 and (reovir\$ or AAV or herpes\$ or EBV or lentivir\$ or retrovir\$)	81	<u>L9</u>
<u>L8</u>	L7 and "AVC2.TK" and 1014	1	<u>L8</u>
<u>L7</u>	(transcomplementary or trans near complementary or trans near complement\$) near5 vector\$ and ("E1" or "E3" or "E4")	70	<u>L7</u>
<u>L6</u>	(transcomplementary or trans near complementary or trans near complement\$) near5 vector\$	96	<u>L6</u>
<u>L5</u>	(transcomplementary or trans near complementary or trans near complement\$) near5 vector\$	95	<u>L5</u>
<u>L4</u>	(transcomplementary or trans near complementary) near5 vector\$	5	<u>L4</u>
<u>L3</u>	L1 and (transcomplementary or trans near complementary) near5 vector\$	2	<u>L3</u>
<u>L2</u>	L1 and (transcomplementary or trans near complementary)	22	<u>L2</u>
<u>L1</u>	adenovir\$ near5 vector\$	14370	<u>L1</u>

END OF SEARCH HISTORY

**Search Results - Record(s) 1 through 95 of 95 returned.**

- 
- ☐ 1. 20030224404 . 24 Feb 03. 04 Dec 03. High throughput directed evolution of nucleic acids by rational mutagenesis. Vega, Manuel, et al. 435/6; 435/320.1 435/325 435/69.1 435/91.2 530/350 536/23.1 C12Q001/68 C07H021/02 C07H021/04 C12P019/34 C12P021/02 C12N005/06.
- 
- ☐ 2. 20030207832 . 23 May 02. 06 Nov 03. Inducible expression vectors and methods of use thereof. Tsang, Thomas Chun-Chang, et al. 514/44; 600/1 A61K048/00 A61N005/00.
- 
- ☐ 3. 20030203488 . 19 Mar 01. 30 Oct 03. Viral vectors and line for gene therapy. Mehtali, Majid, et al. 435/456; 435/235.1 C12N015/86 C12N007/00.
- 
- ☐ 4. 20030203480 . 30 Apr 03. 30 Oct 03. Method of preparing a eukaryotic viral vector. Kovessi, Imre, et al. 435/320.1; 435/235.1 435/456 C12N015/861 C12N007/00.
- 
- ☐ 5. 20030199472 . 19 Mar 03. 23 Oct 03. Adenovirus-mediated therapy for uterine fibroids. Al-Hendy, Ayman, et al. 514/44; 435/6 C12Q001/68 A61K048/00.
- 
- ☐ 6. 20030192066 . 28 May 02. 09 Oct 03. Minimal adenoviral vector. Zhang, Wei-Wei, et al. 800/8; 424/93.2 435/235.1 435/320.1 435/456 536/23.2 800/21 A01K067/00 C07H021/04 A61K048/00 C12N015/861 C12N007/00.
- 
- ☐ 7. 20030186337 . 10 Dec 02. 02 Oct 03. Novel death associated proteins, and THAP1 and PAR4 pathways in apoptosis control. Girard, Jean-Philippe, et al. 435/7.23; 435/226 435/320.1 435/325 435/69.1 536/23.2 G01N033/574 C07H021/04 C12N009/64 C12P021/02 C12N005/06.
- 
- ☐ 8. 20030170885 . 19 Dec 00. 11 Sep 03. Defective adenoviruses and corresponding complementation lines. Imler, Jean-Luc, et al. 435/320.1; 424/93.21 435/235.1 A61K048/00 C12N007/01 C12N015/861.
- 
- ☐ 9. 20030170645 . 02 Apr 02. 11 Sep 03. Bardet-biedl susceptibility gene and uses thereof. Sheffield, Val C., et al. 435/6; 435/183 435/320.1 435/325 435/69.1 536/23.2 C12Q001/68 C07H021/04 C12N009/00 C12P021/02 C12N005/06.
- 
- ☐ 10. 20030167478 . 17 May 01. 04 Sep 03. Novel wounded epithelium-specific transcript. Pilcher, Brian K., et al. 800/8; 435/226 435/320.1 435/325 435/69.1 536/23.2 A01K067/00 C07H021/04 C12N009/64 C12P021/02 C12N005/06.
- 
- ☐ 11. 20030166190 . 10 Dec 02. 04 Sep 03. Nucleic acids related to plant retroelements. Wright, David A., et al. 435/183; 435/200 530/350 530/370 536/23.2 C12N009/00 C12N009/24 C07H021/04 C07K014/415.
- 
- ☐ 12. 20030165462 . 05 Oct 01. 04 Sep 03. Deleted adenovirus vectors and methods of making and administering the same. Amalfitano, Andrea, et al. 424/93.2; 435/235.1 435/320.1 435/456 A61K048/00 C12N015/861 C12N007/00.
- 
- ☐ 13. 20030144205 . 20 Dec 02. 31 Jul 03. Novel germ cell-specific contraceptive target. Matzuk, Martin M., et al. 514/12; 435/226 435/320.1 435/325 435/69.1 530/388.26 536/23.2 A61K038/16 C07H021/04 C12N009/64 C12P021/02 C12N005/06 C07K016/40.
-

- ☐ 14. 20030144204 . 19 Dec 02. 31 Jul 03. Akt-based inducible survival switch. Spencer, David. 514/12; 435/320.1 435/325 514/44 530/350 536/23.5 A61K048/00 C07K014/705 A61K038/17 C07H021/04.
- 
- ☐ 15. 20030143228 . 29 Oct 02. 31 Jul 03. Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen. Chen, Si-Yi, et al. 424/144.1; 435/320.1 435/334 435/69.1 530/388.22 536/23.53 A61K039/395 C07H021/04 C07K016/28 C12P021/02 C12N005/06 C07K014/74.
- 
- ☐ 16. 20030143212 . 12 Nov 02. 31 Jul 03. Corneal cells expressing active agents and methods of use thereof. Williams, Keryn Anne, et al. 424/93.21; 424/85.1 435/368 435/455 A61K048/00 C12N015/85 C12N005/08.
- 
- ☐ 17. 20030138412 . 27 Jun 02. 24 Jul 03. Inhibition of tumor growth and metastasis by N5 gene. Goodrich, David W., et al. 424/93.21; 435/7.23 514/44 A61K048/00 G01N033/574.
- 
- ☐ 18. 20030134351 . 17 Dec 01. 17 Jul 03. High throughput directed evolution by rational mutagenesis. Vega, Manuel, et al. 435/69.1; 435/252.3 435/320.1 435/325 435/456 536/23.2 C12P021/02 C12N005/06 C12N001/21 C07H021/04 C12N015/86 C12N015/74.
- 
- ☐ 19. 20030129203 . 17 Dec 01. 10 Jul 03. Mutant recombinant adeno-associated viruses. Vega, Manuel, et al. 424/233.1; 424/199.1 424/205.1 424/93.2 435/235.1 435/320.1 435/69.1 435/91.1 435/91.33 514/44 A61K031/70 A01N043/04 C12P021/06 C12P019/34 A61K048/00 A01N063/00 A61K039/12 A61K039/23 A61K039/235 C12N007/00 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.
- 
- ☐ 20. 20030108521 . 30 May 02. 12 Jun 03. Adenovirus protein IX, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization. Calatrava, Manuel Rosa. 424/93.2; 424/186.1 435/235.1 435/320.1 435/325 435/456 435/69.3 530/350 536/23.72 A61K048/00 A61K039/12 C07H021/04 C12P021/02 C12N005/06 C07K014/075 C12N007/00 C12N015/861.
- 
- ☐ 21. 20030099615 . 19 Jul 02. 29 May 03. Porcine adenovirus E1 and E4 regions. Tikoo, Suresh K.. 424/93.2; 435/235.1 435/456 514/44 A61K048/00 C12N015/86 C12N007/00.
- 
- ☐ 22. 20030096240 . 12 Sep 01. 22 May 03. Genomic organization of mouse and human sGC. Murad, Ferid, et al. 435/6; 435/199 435/320.1 435/325 435/69.1 536/23.2 C12Q001/68 C07H021/04 C12N009/22 C12P021/02 C12N005/06.
- 
- ☐ 23. 20030087438 . 02 Nov 01. 08 May 03. E1-revertant-free adenoviral composition. Brough, Douglas E., et al. 435/456; 435/235.1 435/239 A61K048/00 C12N015/861 C12N007/02 C12N007/00.
- 
- ☐ 24. 20030083261 . 30 Apr 01. 01 May 03. Class of 12mer peptides that inhibit the function of the mitotic check point protein Mad2. Yu, Hongtao, et al. 514/13; 514/14 514/15 514/16 A61K038/10 A61K038/08.
- 
- ☐ 25. 20030072938 . 24 Jul 02. 17 Apr 03. Trans-lentiviral vector particles and transduction of eukaryotic cells therewith. Kappes, John C., et al. 428/341; 435/69.1 536/23.4 C07H021/04.
- 
- ☐ 26. 20030072758 . 21 May 02. 17 Apr 03. BMPRI A involvement in juvenile polyposis. Howe, James R.. 424/155.1; 435/6 435/7.23 C12Q001/68 G01N033/574 A61K039/395.
- 
- ☐ 27. 20030054553 . 23 Jul 01. 20 Mar 03. Adenovector complementing cells. Brough, Douglas E., et al. 435/456; 435/235.1 435/320.1 435/366 C12N015/861 C12N007/00 C12N005/08.

- ☐ 28. 20030044385 . 02 Apr 02. 06 Mar 03. Tumour-specific vector for gene therapy. Kupper, Jan-Heiner, et al. 424/93.2; 435/235.1 435/320.1 435/456 A61K048/00 C12N007/00 C12N015/861.
- 
- ☐ 29. 20030040100 . 23 Jul 01. 27 Feb 03. Cell for the propagation of adenoviral vectors. Brough, Douglas E., et al. 435/235.1; 435/239 435/325 536/23.72 536/24.1 C12N007/02 C12N005/02 C07H021/04 C12N005/00 C12N007/01 C12N007/00.
- 
- ☐ 30. 20030031649 . 01 May 02. 13 Feb 03. Gene therapy to promote angiogenesis. Jan van Zonneveld, Anton, et al. 424/93.2; 435/456 A61K048/00 C12N015/869.
- 
- ☐ 31. 20030017595 . 23 Jul 01. 23 Jan 03. Non-adenoviral gene product-based complementing cells for adenoviral vectors. Brough, Douglas E., et al. 435/456; 435/235.1 435/320.1 435/366 C12N015/861 C12N007/01 C12N005/08.
- 
- ☐ 32. 20030008375 . 27 Dec 01. 09 Jan 03. Methods for treating patients with adenoviral vectors. Zhang, Shuyuan, et al. 435/235.1; 435/239 435/456 C12N007/00 C12N007/02 C12N015/861.
- 
- ☐ 33. 20030008282 . 06 Jun 01. 09 Jan 03. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening. Capon, Daniel J., et al. 435/6; 435/320.1 435/5 C12Q001/68 C12Q001/70 C12N015/869.
- 
- ☐ 34. 20020182723 . 12 Jun 01. 05 Dec 02. AN IMPROVED METHOD FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS. Zhang, Shuyuan, et al. 435/320.1; 424/233.1 435/235.1 435/239 536/23.72 536/24.1 C12N007/01 C12N015/861 C07H021/04 A61K039/235.
- 
- ☐ 35. 20020177215 . 27 Dec 01. 28 Nov 02. Methods for producing purified adenoviral vectors. Zhang, Shuyuan, et al. 435/235.1; 435/239 435/456 C12N007/00 C12N007/02 C12N015/861.
- 
- ☐ 36. 20020164802 . 01 May 02. 07 Nov 02. Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer. Fallaux, Frits J., et al. 435/456; 435/235.1 435/325 C12N015/861 C12N007/00 C12N005/06.
- 
- ☐ 37. 20020164783 . 19 Jul 01. 07 Nov 02. Transcriptionally-activated AAV inverted terminal repeats (ITRs) for use with recombinant AAV vectors. Feldhaus, Andrew L.. 435/320.1; 424/159.1 424/199.1 424/204.1 424/233.1 435/173.9 435/235.1 435/239 435/91.1 435/91.33 514/44 C12P019/34 A61K039/42 C12N013/00 A61K039/12 A61K039/23 A61K039/235 C12N007/00 C12N007/01 C12N007/02 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 A61K031/70 A01N043/04.
- 
- ☐ 38. 20020150931 . 18 Dec 01. 17 Oct 02. Bardet-biedl susceptibility gene and uses thereof. Sheffield, Val, et al. 435/6; 435/183 435/320.1 435/325 435/69.1 435/7.92 536/23.2 C12Q001/68 G01N033/53 G01N033/537 G01N033/543 C07H021/04 C12N009/00 C12P021/02 C12N005/06.
- 
- ☐ 39. 20020142989 . 22 May 02. 03 Oct 02. Oncolytic/immunogenic complementary-adenoviral vector system. Alemany, Ramon, et al. 514/44; 424/93.2 435/235.1 435/320.1 435/456 A61K048/00 C12N015/861.
- 
- ☐ 40. 20020137889 . 17 Sep 01. 26 Sep 02. Stress resistant retroviruses. Soong, Nay Wei, et al. 530/350; 435/235.1 435/325 435/69.1 536/23.72 C12N007/01 C12P021/02 C07H021/04 C07K014/15 C12N005/06.
- 
- ☐ 41. 20020127711 . 27 Dec 00. 12 Sep 02. Process for ex vivo formation of mammalian bone and

uses thereof. Kale, Sujata, et al. 435/325; 424/423 435/366 C12N005/00 C12N005/02 C12N005/08.

- 
- ☐ 42. 20020090717 . 16 Jan 02. 11 Jul 02. Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus. Gao, Guangping, et al. 435/239; 435/235.1 435/367 435/455 435/456 435/464 435/465 435/476 435/70.3 C12P021/04 C12N007/00 C12N007/01 C12N007/02 C12N005/08 C12N015/63 C12N015/85 C12N015/87 C12N015/86 C12N015/74.
- 
- ☐ 43. 20020088014 . 10 Oct 01. 04 Jul 02. Minimal adenovirus mediated recombinant vaccine. Fang, Xiangming, et al. 800/8; 435/235.1 435/320.1 435/456 A01K067/00 C12N015/867 C12N015/861 C12N007/00 C12N007/01.
- 
- ☐ 44. 20020072120 . 03 Aug 01. 13 Jun 02. Helper viruses for the preparation of recombinant viral vectors. Lusky, Monika, et al. 435/457; 435/235.1 435/325 435/69.1 C12N015/861 C12N007/00 C12P021/02 C12N005/06.
- 
- ☐ 45. 20020068050 . 11 Apr 01. 06 Jun 02. Corneal cells expressing active agents and methods of use thereof. Williams, Keryn Anne, et al. 424/93.21; 435/320.1 435/455 A61K048/00 C12N015/87.
- 
- ☐ 46. 20020051763 . 06 May 99. 02 May 02. HOST-VECTOR SYSTEM WHICH CAN BE USED IN GENE THERAPY. KLATZMANN, DAVID, et al. 424/93.2; 424/93.21 435/320.1 435/325 435/455 435/458 514/44 A61K048/00 C12N015/88 C12N015/87 C12N005/06.
- 
- ☐ 47. 20020042139 . 31 May 01. 11 Apr 02. Methods and compositions for efficient gene transfer using transcomplementary vectors. Higginbotham, James N., et al. 435/457; C12N015/861.
- 
- ☐ 48. 20020034732 . 30 Jul 98. 21 Mar 02. COMPOSITIONS AND METHODS FOR DETERMINING ANTI-VIRAL DRUG SUSCEPTIBILITY AND RESISTANCE AND ANTI-VIRAL DRUG SCREENING. CAPON, DANIEL J., et al. 435/5; 435/252.3 435/32 435/320.1 435/6 C12Q001/70 C12Q001/68 C12Q001/18 C12P013/14 C12N001/20 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.
- 
- ☐ 49. 20010049136 . 30 Nov 00. 06 Dec 01. Defective adenoviruses and corresponding complementation lines. Imler, Jean-Luc, et al. 435/320.1; 435/235.1 435/325 C12N015/861 C12N007/01 C12N005/06.
- 
- ☐ 50. 6517828 . 26 May 00; 11 Feb 03. C-CAM as an angiogenesis inhibitor. Lin; Sue-Hwa, et al. 424/93.2; 435/320.1 514/44 530/350 536/23.5. C12N015/79 A61K048/00.
- 
- ☐ 51. 6489537 . 15 Jul 99; 03 Dec 02. Phytochelatin synthases and uses therefor. Rea; Philip A., et al. 800/278; 435/320.1 435/419 435/468 435/69.1 536/23.1 536/23.2 536/23.6 536/23.7 800/288 800/295 800/298 800/306 800/320.3. C12N015/09 C12N015/29 C12N015/31 C12N015/82 A01H005/00.
- 
- ☐ 52. 6489142 . 25 Jan 01; 03 Dec 02. Methods and compositions for producing viral particles. Torrent; Christophe, et al. 435/69.1; 435/6 435/69.7 530/387.3 536/23.4 536/23.72. C12P021/06 C12P021/04 C12P021/08 C12Q001/68 C07H021/04.
- 
- ☐ 53. 6479290 . 27 Jan 00; 12 Nov 02. Chimeric adenoviral vectors. Mehtali; Majid, et al. 435/457; 435/235.1 435/320.1 435/455 435/91.33 435/91.4 536/23.1. C12N015/861 C12N015/86 C12N007/01 C12N015/09 C07H021/04.
- 
- ☐ 54. 6475480 . 06 Jul 99; 05 Nov 02. Use of adenoviral E4 reading frames to improve expression of a gene of interest. Mehtali; Majid, et al. 424/93.2; 435/235.1 435/320.1 435/440 435/455 435/456

514/44. A01N063/00 A01N043/04 C12N015/00 C12N007/00 C12N015/63.

- 
- ☐ 55. 6423491 . 13 May 99; 23 Jul 02. Method of diagnosing juvenile polyposis (JP). Howe; James R., et al. 435/6; 435/4 435/7.1 435/7.21 435/7.23 435/7.92 435/7.95 436/63 436/64. C12Q001/00 C12Q001/68 G01N033/567 G01N033/574 G01N033/53.
- 
- ☐ 56. 6420335 . 16 Jun 99; 16 Jul 02. Combination of radiotherapy and anti-angiogenic factors. Weichselbaum; Ralph R., et al. 514/2; 378/65 514/1 530/350 600/1. A01N037/18 A01N005/10 A01N061/00 A01N005/00 C07K001/00.
- 
- ☐ 57. 6403370 . 10 Feb 97; 11 Jun 02. Oncolytic/immunogenic complementary-adenoviral vector system. Alemany; Ramon, et al. 435/320.1; 435/455 435/456 435/457. C12N015/861.
- 
- ☐ 58. 6395519 . 23 Apr 99; 28 May 02. Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer. Fallaux; Frits J., et al. 435/91.42; 435/320.1 435/325 435/366 435/368 435/369 435/371 435/455 435/456 435/457 435/69.1 435/91.4. C12N005/10 C12N015/10 C12N015/63 C12N015/64 C12N015/861.
- 
- ☐ 59. 6365394 . 11 Sep 00; 02 Apr 02. Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus. Gao; Guangping, et al. 435/239; 435/235.1 435/367 435/455 435/456 435/464 435/465 435/476 435/70.3. C12N007/00 C12N015/64 C12N007/02 C12P001/00.
- 
- ☐ 60. 6350575 . 02 May 00; 26 Feb 02. Helper viruses for the preparation of recombinant viral vectors. Lusky; Monika, et al. 435/5; 435/320.1 435/325 435/366 435/369 435/455 435/456 435/457 435/462 435/6 435/69.1 435/91.42. C12Q001/68 C12Q001/70 C12N015/861 C12N015/64 C12N005/10.
- 
- ☐ 61. 6346415 . 20 Oct 98; 12 Feb 02. Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors. Feldhaus; Andrew L.. 435/320.1; 435/235.1 435/325 435/440 435/455 435/456 435/457 536/24.1. C12N015/864 C12N007/01 C12N005/10.
- 
- ☐ 62. 6328958 . 27 Aug 99; 11 Dec 01. Deleted adenovirus vectors and methods of making and administering the same. Amalfitano; Andrea, et al. 424/93.2; 435/320.1 435/455 435/91.4 514/44. A61K048/00 C12N015/88.
- 
- ☐ 63. 6248514 . 18 Aug 98; 19 Jun 01. Methods for measuring viral infectivity. Hutchins; Beth M., et al. 435/5; 435/3 435/4 435/7.1. C12Q001/70 C12Q003/00 C12Q001/00 G01N033/53.
- 
- ☐ 64. 6242187 . 10 Aug 99; 05 Jun 01. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening. Capon; Daniel J., et al. 435/6; 435/320.1 435/369 435/370. C12Q001/68.
- 
- ☐ 65. 6235881 . 23 Feb 99; 22 May 01. Polypeptides encoded by novel HIV-2 proviruses. Kraus; Gunter, et al. 530/350; 530/387.3 536/23.72. C07K001/00 C07K016/00 C07H021/04.
- 
- ☐ 66. 6204060 . 31 Mar 97; 20 Mar 01. Viral vectors and line for gene therapy. Mehtali; Majid, et al. 435/456; 435/320.1 435/325 435/366 435/369 435/370. C12N015/86 C12N005/10 C12N015/63.
- 
- ☐ 67. 6194191 . 20 Nov 97; 27 Feb 01. Method for the production and purification of adenoviral vectors. Zhang; Shuyuan, et al. 435/239; 424/199.1 435/235.1 435/320.1. C12N007/02 C12N007/01.
- 
- ☐ 68. 6133028 . 30 Sep 99; 17 Oct 00. Defective adenoviruses and corresponding complementation

lines. Imler; Jean-Luc, et al. 435/325; 424/93.2 435/320.1 435/456. C12N005/10 C12N015/34 C12N015/86.

- 
- ☐ 69. 6066478 . 09 Mar 98; 23 May 00. Helper viruses for preparing recombinant viral vectors. Lusky; Monika, et al. 435/91.41; 435/320.1 435/325 435/366 435/369 435/455 435/456 435/457 435/91.4 435/91.42 536/23.2 536/23.4 536/23.5 536/23.7. C12N015/64 C12N015/861 C12N005/10 C07H021/04.
- 
- ☐ 70. 6040174 . 26 Jan 95; 21 Mar 00. Defective adenoviruses and corresponding complementation lines. Imler; Jean-Luc, et al. 435/325; 424/93.2 435/320.1 435/456. C12N005/10 C12N015/86 C12N015/34.
- 
- ☐ 71. 5994106 . 26 Nov 96; 30 Nov 99. Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus. Koveshi; Imre, et al. 435/91.4; 435/320.1 435/325 435/366 435/456. C12N005/10 C12N015/64 C12N015/86.
- 
- ☐ 72. 5981225 . 16 Apr 98; 09 Nov 99. Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same. Kochanek; Stefan, et al. 435/69.1; 435/320.1 435/456 435/457 536/23.5 536/23.72 536/24.1. C12P021/00 C12N007/01 C12N015/12 C12N015/33.
- 
- ☐ 73. 5965358 . 26 Aug 98; 12 Oct 99. Method for assessing the relative purity of viral gene transfer vector stocks. Carrion; Miguel, et al. 435/5; 250/283 250/287 435/173.9 435/6. C12Q001/68 C12Q001/70 B01D059/44.
- 
- ☐ 74. 5958768 . 23 Aug 96; 28 Sep 99. Chimeric antiviral agents comprising Rev binding nucleic acids and trans-acting ribozymes, and molecules encoding them. Kraus; Gunter, et al. 435/372.3; 435/320.1 435/325 435/366 435/455 536/24.5. C07H021/04 C12N005/16 C12N005/22 C12N015/79 C12N015/85.
- 
- ☐ 75. 5948675 . 04 Oct 96; 07 Sep 99. Host-vector system which can be used in gene therapy. Klatzmann; David, et al. 435/320.1; 424/93.21 435/325 435/455 435/69.1 514/44 536/23.1. C12N015/00.
- 
- ☐ 76. 5939538 . 19 Dec 96; 17 Aug 99. Methods and compositions for inhibiting HIV infection of cells by cleaving HIV co-receptor RNA. Leavitt; Markley C., et al. 536/23.1; C07H021/02.
- 
- ☐ 77. 5891690 . 26 Apr 96; 06 Apr 99. Adenovirus E1-complementing cell lines. Massie; Bernard. 435/456; 435/235.1 435/371. C12N005/10 C12N015/86 C12N015/87.
- 
- ☐ 78. 5883081 . 07 Jun 96; 16 Mar 99. Isolation of novel HIV-2 proviruses. Kraus; Gunter, et al. 514/44; 424/160.1 435/320.1 435/69.1 530/388.35 536/23.1. A01N043/04 A61K039/42 C12P021/06 C12N015/00.
- 
- ☐ 79. 5882862 . 09 May 96; 16 Mar 99. Human radioresistance/cell cycle progression gene. Davey; Scott K., et al. 435/6; 536/23.1. C12Q001/68 C07H021/04.
- 
- ☐ 80. 5747243 . 22 Mar 96; 05 May 98. Retrovirus detection method. Gruber; Harry E., et al. 435/5; 435/7.1 435/7.2. C12Q001/70 G01N033/53 G01N033/567.
- 
- ☐ 81. 5741706 . 25 Sep 96; 21 Apr 98. Anti-HIV ribozymes. Leavitt; Markley C., et al. 435/372; 435/320.1 435/325 435/366 435/6 435/91.31 536/23.1 536/23.2 536/24.5. C12N015/85 C12Q001/68.
-

- ☐ 82. 5503974 . 13 Aug 93; 02 Apr 96. Retrovirus detection. Gruber; Harry E., et al. 435/5; 435/7.21 435/7.24. C12Q001/70 G01N033/567 G01N033/53 G01N033/555.
- 
- ☐ 83. 5252465 . 25 Jun 90; 12 Oct 93. Avian erythroblastosis virus vectors for integration and expression of heterologous genes in avian cells. Nigon; Victor-Marc, et al. 435/69.1; 435/239 435/320.1 435/349 435/467. C12N015/86 C12N005/10 C12N007/01 C12P021/00.
- 
- ☐ 84. EP 1104813 A1 . 01 Dec 99. 06 Jun 01. Conditional replication of recombinant human adenovirus DNA carrying modified inverted terminal repeat sequences. RADEMAKER, HENDRIK JAN, et al. C12N015/86;.
- 
- ☐ 85. WO 9854345 A1 . 19 May 98. 03 Dec 98. MINI-ADENOVIRAL VECTOR. ZHANG, WEI-WEI, et al. C12N015/86; C12N015/34 C12N005/10 C12N007/01 A61K035/76 A01K067/027.
- 
- ☐ 86. WO 9745550 A2 . 30 May 97. 04 Dec 97. MINI-ADENOVIRAL VECTOR. ZHANG, WEI-WEI, et al. C12N015/86; C12N015/34 C12N005/10 C12N007/01 A61K035/76 A01K067/027.
- 
- ☐ 87. WO 200261103 A1 FR 2820146 A1 . Preparing retroviral packaging cells, useful for producing e.g. gene therapy vectors, by selecting trans-complementing cells, non-permissive for retroviral infection. GAUTIER, R, et al. C12N005/10 C12N007/01 C12N015/64 C12N015/86 C12N015/867.
- 
- ☐ 88. US 20030203480 A1 WO 200231169 A1 AU 200213133 A US 6573092 B1 . Producing eukaryotic vector, by contacting eukaryotic cell having enzyme that nicks/cleaves DNA molecule, with recombinant phage vector, or contacting cell not comprising the enzyme with the enzyme and phage vector. KOVESDI, I, et al. C12N007/00 C12N015/80 C12N015/86 C12N015/861 C12N015/87 C12N015/90.
- 
- ☐ 89. EP 1287153 A2 WO 200192550 A2 AU 200165219 A US 20020042139 A1 . New compositions comprising transcomplementary vectors, useful in genetic engineering protocols (e.g. gene delivery, antisense type strategies, diagnosis or gene therapy) to increase gene transfer efficiency of viral vectors. HIGGINBOTHAM, J N, et al. A61K048/00 C12N005/10 C12N015/86 C12N015/861 C12N015/867 C12N015/869 G01N033/15.
- 
- ☐ 90. WO 200018906 A2 AU 200011990 A EP 1117777 A2 EP 1130093 A1 KR 2001085850 A MX 2001003212 A1 JP 2002537758 W . Novel methods for recombining codon-altered libraries of nucleic acids used to produce new proteins and new vectors with reduced rates of reversion to wild type. LIU, L, et al. A61K039/21 B01J019/00 C07B061/00 C12N001/21 C12N005/10 C12N007/00 C12N007/04 C12N015/09 C12N015/10 C12N015/11 C12N015/12 C12N015/49 C12N015/55 G06F019/00 C12N015/12 C12N015/49 C12N015/55.
- 
- ☐ 91. AU 756607 B EP 974668 A1 CA 2276791 A1 JP 2000106875 A AU 9938009 A EP 974668 B1 US 6475480 B1 DE 69903229 E ES 2180258 T3 . Novel vector used for gene transfer methods, e.g. gene therapy. LUSKY, M, et al. A01N043/04 A01N063/00 A61K031/70 A61K048/00 A61P003/10 A61P007/00 A61P009/00 A61P031/12 A61P031/18 A61P035/00 A61P037/06 C07K014/075 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N007/00 C12N007/01 C12N007/02 C12N015/00 C12N015/09 C12N015/34 C12N015/63 C12N015/86.
- 
- ☐ 92. US 6566128 B1 WO 9813510 A1 EP 938579 A1 US 6080569 A JP 2000514312 W . Improved helper-dependent vector system comprising loxP sites - used for production of high capacity adenoviral cloning vector(s). CHEN, L, et al. A61K048/00 C12N005/00 C12N005/10 C12N007/00 C12N015/09 C12N015/63 C12N015/74 C12N015/83 C12N015/86 C12Q001/66 C12Q001/70.
- 
- ☐ 93. US 20020123146 A1 WO 9802529 A1 FR 2751345 A1 EP 912723 A1 JP 2000514652 W .



Eukaryotic packaging cell for production of defective infectious virus for gene therapy - has defect complemented by gene on vector carrying the trans-gene or trans-complementing functions. KLATZMANN, D, et al. A61K048/00 A61P035/00 A61P037/00 C12N005/08 C12N005/10 C12N007/01 C12N015/09 C12N015/86 C12N015/867.

☐ 94. CA 2177085 A US 5891690 A . Adenovirus E1-complementing cell lines for producing defective adenoviral vectors - comprising stably integrated complementation element, but lacking 5'-terminal repeat, packaging sequence and E1A promoter. MASSIE, B. C12N005/10 C12N007/01 C12N015/34 C12N015/86 C12N015/87.

☐ 95. FR 2741358 A1 WO 9719182 A1 . Production of retroviral vectors in eukaryotic cells - uses DNA virus containing retroviral elements for cell infection and related DNA containing transcription unit, vector and infected cells, for gene therapy. COSSET, F L, et al. A61K048/00 C07K014/15 C12N005/10 C12N007/01 C12N007/04 C12N015/79 C12N015/86.

[Generate Collection](#)[Print](#)

Terms	Documents
(trnascomplementary or trans near complementary or trans near complement\$) near5 vector\$	95

[Previous Page](#)[Next Page](#)



## Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.  
Additionally, enter the **first few letters** of the Inventor's First name.

**Last Name****First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



## Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.  
Additionally, enter the **first few letters** of the Inventor's First name.

**Last Name****First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



## Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.  
Additionally, enter the **first few letters** of the Inventor's First name.

**Last Name****First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)